ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
A Comparative Study on the Value of Blood Cellular Indices in Predicting the Outcomes in End Stage Renal Disease.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundEnd Stage Renal Disease (ESRD) is the final stage of chronic kidney disease (CKD), where patients retain only <15% of their kidney function. Recent studies on neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) have demonstrated strong predictive utility in ESRD progression; however, there is limited research on ESRD prognosis in relation to additional blood cellular indices. In this study, 11 blood cellular indices, both well-established and lesser-known markers, were evaluated in relation to ESRD as potential prognostic tools.MethodsData was sourced from Loyola University Medical Center (LUMC) clinical database, comparing ESRD patients (n=67) with healthy, non-ESRD ambulatory patients (n=102), randomly identified in 2023. Median, interquartile ranges (IQR), p-values, and fold changes were calculated, clinical and demographic information was collected, and a Spearman correlation matrix was generated on R.ResultsThe Mann-Whitney U test revealed significant differences (p<0.05) in most indices between the two groups, except for the (PLR) with differing fold changes from the healthy ambulatory cohort. The Spearman Correlation matrix indicated weak (0.0-0.2), moderate (0.21-0.6), and strong (0.61-1.0) positive and negative correlations between previously studied indices and indices in this study.ConclusionsDespite variability within each cohort, these results highlight the potential of additional blood cellular indices to serve as prognostic markers in ESRD mortality, inflammation, and cardiovascular disease. This study provides the basis for evaluating these indices in a longitudinal manner to assess disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.